APRILE: Exploring the Molecular Mechanisms of Drug Side Effects with Explainable Graph Neural Networks
Xu, H.; Sang, S.; Yao, H.; Herghelegiu, A. I.; Lu, H.; Yang, L.
Show abstract
The majority of people over the age of 65 take two or more medications. While many individual drug side effects are known, polypharmacy side effects due to novel drug combinations poses great risk. Here, we present APRILE: an explainable artificial intelligence (XAI) framework that uses graph neural networks to explore the molecular mechanisms underlying polypharmacy side effects. Given a list of side effects and the pairs of drugs causing them, APRILE identifies a set of proteins (drug targets or non-targets) and associated Gene Ontology (GO) terms as mechanistic explanations of associated side effects. Using APRILE, we generate such explanations for 843,318 (learned) and 93,966 (novel) side effect-drug pair events, spanning 861 side effects (472 diseases, 485 symptoms and 9 mental disorders) and 20 disease cate-gories. We show that our two new metrics--pharmacogenomic information utilization and protein-protein interaction information utilization--provide quantitative estimates of mechanism complexity. Explanations were significantly consistent with state of the art disease-gene associations for 232/239 (97%) side effects. Further, APRILE generated new insights into molecular mechanisms of four diverse categories of adverse drug reactions: infection, metabolic diseases, gastrointestinal diseases, and mental disorders, including paradoxical side effects. We demonstrate the viability of discovering polypharmacy side effect mechanisms by training an XAI framework on massive biomedical data. Consequently, it facilitates wider and more reliable use of AI in healthcare.
Matching journals
The top 5 journals account for 50% of the predicted probability mass.
Similar papers in this journal
- Tissue-guided LASSO for prediction of clinical drug response using preclinical samples 95%
- A machine learning and network framework to discover new indications for small molecules 94%
- Controlling astrocyte-mediated synaptic pruning signals for schizophrenia drug repurposing with Deep Graph Networks 94%
Similar papers in this journal
- Random Walk with Restart on multilayer networks: from node prioritisation to supervised link prediction and beyond 95%
- Drug mechanism enrichment analysis improves prioritization of therapeutics for repurposing 95%
- COMIC: Explainable Drug Repurposing via Contrastive Masking for Interpretable Connections 95%
Similar papers in this journal
- SynDRep: A Knowledge Graph-Enhanced Tool based on Synergistic Partner Prediction for Drug Repurposing 94%
- Mapping drug biology to disease genetics to discover drug impacts on the human phenome 94%
- Latent disease similarities and therapeutic repurposing possibilities uncovered by multi-modal generative topic modeling of human diseases 93%
Similar papers in this journal
- G-PLIP: Knowledge graph neural network for structure-free protein-ligand bioactivity prediction 93%
- DrugForm-DTA: Towards real-world drug-target binding Affinity Model 93%
- Genome-wide associations spanning 194 in-hospital drug dosage change phenotypes highlight diverse genetic backgrounds in concurrent drug therapy 93%
"Similar papers" are the closest papers from that journal in the model's embedding space. They show what the match is built on, but the ranking comes mostly from a classifier over the whole training set, not from these examples alone.